REEP6 as a Radioligand Therapy Target
REEP6, receptor accessory protein 6, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, REEP6 staining is highest in thyroid cancer (100% of samples positive), head and neck cancer (100% of samples positive) and melanoma (100% of samples positive). Evidence on whether REEP6 internalizes is mixed. Clinical status: Discovery-stage (no clinical drug program).
Is REEP6 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
REEP6 expression in cancer
Protein expression of REEP6 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.89 | High | 100% |
| Head and Neck Cancer | 0.83 | High | 100% |
| Melanoma | 0.75 | High | 100% |
| Cervical Cancer | 0.67 | High | 100% |
| Prostate Cancer | 0.67 | High | 100% |
| Glioma | 0.64 | High | 100% |
| Pancreatic Cancer | 0.61 | High | 100% |
| Bladder Cancer | 0.58 | High | 100% |
| Liver Cancer | 0.58 | High | 100% |
| Lung Cancer | 0.58 | High | 91% |
| Gastric Cancer | 0.55 | High | 100% |
| Breast Cancer | 0.53 | High | 100% |
| Colorectal Cancer | 0.50 | Medium | 100% |
| Ovarian Cancer | 0.50 | Medium | 100% |
| Neuroendocrine Tumors | 0.50 | Medium | 75% |
| Skin Cancer | 0.47 | Medium | 92% |
| Endometrial Cancer | 0.46 | Medium | 91% |
| Kidney Cancer | 0.39 | Medium | 83% |
| Lymphoma | 0.31 | Medium | 83% |
| Testicular Cancer | 0.28 | Medium | 75% |
Is REEP6 internalized?
Uncertain. Insufficient literature found.
Sources: PMID 27966653. AI-extracted from abstracts, so verify before citing.
REEP6 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for REEP6 yet. Search ClinicalTrials.gov for REEP6 trials.
REEP6 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See REEP6 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
REEP6 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how REEP6 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.